Candesartan may prevent aneurysmal changes in the residual native aorta after thoracic aortic aneurysm surgery

Candesartan may prevent aneurysmal changes in the residual native aorta after thoracic aortic aneurysm surgery - CAPTAIN Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000756

Enrollment

150

Registered

2007-07-01

Start date

2007-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic aortic aneurysm

Interventions

Administration of Cnadesartan Administration of antihypertensive drug other than Candesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hypertention who underwent thoracic aortic surgery

Exclusion criteria

Exclusion criteria: Patients with contraindication for Candesartan Patients with allergic reaction to Candesartan Pregnant or potentially pregnant Patients who did not consent to the study Patients under 20 years of age Others who are not suitable to the enrollment from the physician's point of view

Design outcomes

Primary

Measure	Time frame
Changes in the aortic diameter	—

Secondary

Measure	Time frame
Pulse wave velocity	—

Countries

Japan

Contacts

Public ContactYoshikatsu Saiki

Graduate School of Medicine, Tohoku University Department of Cardiovascular Surgery

ysaiki@mail.tains.tohoku.ac.jp022-717-7222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026